KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) Meeting Abstract
| Authors: | Rugo, H. S.; Llombart-Cussac, A.; Andre, F.; Robson, M. E.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Ahn, J. S.; Nanda, R.; Bardia, A.; Fan, L.; Mejia, J. A.; Karantza, V. |
| Abstract Title: | KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368309176 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.TPS596 |
| Notes: | Meeting Abstract: TPS596 -- Source: Wos |
